Re: Farmas USA
ARQL
Una que parece que muere
El partner, Kyowa Hakko Kirin Announces Top-Line Results of Japanese Phase 3 Clinical Study of ARQ197 (tivantinib) in Hepatocellular Carcinoma
The primary endpoint is progression-free survival (PFS), and the top-line results did not
show a significant difference in PFS, between the tivantinib group and the placebo group.
$40m and debt/payables $23m... 71m shares o/s = net cash roughly 23-25 cents/share as of March 31st.
http://www.kyowa-kirin.com/news_releases/2017/pdf/e20170327_01.pdf
«Después de nada, o después de todo/ supe que todo no era más que nada.»